Incyclix Bio Expands Board of Directors with Appointment of Norman E. Sharpless, MD RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...

Incyclix Bio Announces Abstract Accepted for Presentation at 2024 San Antonio Breast Cancer Symposium RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...

Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...

Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer –  INX-315 is a novel, potent and selective inhibitor of CDK2 with compelling pre-clinical efficacy and safety data–  First-in-human, Phase 1/2 study of INX-315 in patients with ER+/HER2- breast...

Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital to join Incyclix Bio’s board of directors RESEARCH...